Literature DB >> 7734347

Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto)

L Pagano1, P Ricci, A Nosari, A Tonso, M Buelli, M Montillo, L Cudillo, A Cenacchi, C Savignana, L Melillo.   

Abstract

A retrospective study on a consecutive series of 116 patients affected by acute leukaemia with documented pulmonary filamentous mycosis (FM) admitted between 1987 and 1992 to 14 tertiary-care hospitals in Italy was made in order to evaluate the characteristics of those patients who developed fatal massive haemoptysis. In 59/116 cases of pulmonary FM the infection was the principal cause of death and in 12 of these patients a massive haemoptysis was responsible for death. The diagnosis of FM infection was made ante-mortem in only four out of these 12 patients. The autopsy was performed in 11/12 patients and documented a FM infection. The mycetes isolated were: Hyphomycetes spp. (three patients), Mucorales spp. (two patients), Aspergillus spp. (seven patients). At the time of the massive haemoptysis the mean neutrophil count was 7.2 x 10(9)/l, and no patient had relevant thrombocytopenia (mean 184 x 10(9)/l, range 28-350) or coagulative abnormalities. The mean time which elapsed between resolution of chemotherapy-induced neutropenia (WBC < 10(9)/l) and occurrence of haemoptysis was 7 d. No signs or symptoms predictive of this fatal complication were identified. Massive haemoptysis can be the cause of death in patients with acute leukaemia and pulmonary FM which in the majority of patients was not diagnosed in vivo. This complication occurs most frequently shortly after the recovery from chemotherapy-induced aplasia. The mechanism of lesion is unknown, but it may involve the vascular tropism of FM and the release of leucocyte enzymes. Better preventive and therapeutic antifungal treatments are needed to avoid this serious, albeit rare, complication.

Entities:  

Mesh:

Year:  1995        PMID: 7734347     DOI: 10.1111/j.1365-2141.1995.tb08355.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Authors:  Brahm H Segal; Raoul Herbrecht; David A Stevens; Luis Ostrosky-Zeichner; Jack Sobel; Claudio Viscoli; Thomas J Walsh; Johan Maertens; Thomas F Patterson; John R Perfect; Bertrand Dupont; John R Wingard; Thierry Calandra; Carol A Kauffman; John R Graybill; Lindsey R Baden; Peter G Pappas; John E Bennett; Dimitrios P Kontoyiannis; Catherine Cordonnier; Maria Anna Viviani; Jacques Bille; Nikolaos G Almyroudis; L Joseph Wheat; Wolfgang Graninger; Eric J Bow; Steven M Holland; Bart-Jan Kullberg; William E Dismukes; Ben E De Pauw
Journal:  Clin Infect Dis       Date:  2008-09-01       Impact factor: 9.079

2.  Cavitary pulmonary zygomycosis caused by Rhizopus homothallicus.

Authors:  Arunaloke Chakrabarti; Rungmei S K Marak; M R Shivaprakash; Sunita Gupta; Rajiv Garg; V Sakhuja; Sanjay Singhal; Abhishek Baghela; Ajai Dixit; M K Garg; Arvind A Padhye
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

3.  Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition.

Authors:  Simone A Nouér; Marcio Nucci; Naveen Sanath Kumar; Monica Grazziutti; Bart Barlogie; Elias Anaissie
Journal:  Clin Infect Dis       Date:  2011-08-16       Impact factor: 9.079

Review 4.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

Review 5.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

6.  Invasive pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases.

Authors:  Lei Qiu; Jingsong He; Xiujin Ye; Wanzhuo Xie; Jimin Shi; Weiyan Zheng; Jie Sun; Xiaoli Zhu; Zhen Cai; He Huang; Maofang Lin
Journal:  Int J Hematol       Date:  2009-05-30       Impact factor: 2.490

7.  Successful Off-Label Use of Recombinant Factor VIIa and Coil Embolization in an Adolescent with Massive Hemoptysis Due to Invasive Pulmonary Aspergillosis.

Authors:  Dilek Gürlek Gökçebay; Ali Fettah; İsmail Kırbaş; Bahattin Tunç; Namık Yaşar Özbek
Journal:  Turk J Haematol       Date:  2015-03-05       Impact factor: 1.831

8.  Case Report: Metagenomics Next-Generation Sequencing for Diagnosing Cerebral Infarction and Infection Caused by Hematogenous Disseminated Mucormycosis in a Patient With Acute Lymphoblastic Leukemia.

Authors:  Bingbing Wen; Lisheng Cai; Yun Cai; Xin Du
Journal:  Front Med (Lausanne)       Date:  2021-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.